Stories about Forschung

Subscribe to topic
Subscribe to Forschung
Language:
english
Content:
All
Date:
All
Yesterday
Last 7 days
December
Reset
11.10.2018 – 12:00

Debiopharm International SA

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic product in Oncology

Lausanne, Villigen, Switzerland (ots) - Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a ...
08.05.2018 – 09:00

Debiopharm International SA

FDA Grants Fast Track designation to Debiopharm International's Debio 1347 for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration

Lausanne, Switzerland (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an FGFR 1-3 Inhibitor, for the ...
23.04.2018 – 12:00

Grünenthal Group

Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)

Aachen (ots) - Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal's research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and Chief Scientific Officer at Sanofi's German Hub in Frankfurt. Philip is a senior leader with extensive experience in drug discovery and ...
09.04.2018 – 09:30

Grünenthal Group

Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment

Aachen and Leuven, Belgium (ots) - Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need. The partnership builds on lead compounds jointly developed by CD3 and LICR as ...
15.02.2018 – 09:00

Debiopharm International SA

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections

Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
28.11.2017 – 14:00

Debiopharm International SA

GenePOC Launches its GenePOC(TM) CDiff test in the United States / GenePOC announces the launch and FDA clearance of its Clostridium difficile molecular test in US

Québec, Canada (ots) - GenePOC Inc. (GenePOC), a member of the Debiopharm Group(TM), is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months, GenePOC(TM) CDiff, for use on the revogene(TM) instrument. The GenePOC CDiff test targets the toxin B gene of toxigenic C. difficile strains in ...
12.10.2017 – 09:01

Debiopharm International SA

GenePOC Launches its new GenePOC(TM) GBS DS test / GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe

Québec, Canada (ots) - GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce the launch of its 2nd assay this year, GenePOC(TM) GBS DS[1], for use on the revogene(TM) instrument. GenePOC GBS DS at intrapartum will aid to minimize the risk of GBS transmission from the mother to their ...
03.10.2017 – 14:01

Debiopharm International SA

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)

Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
10.05.2017 – 11:00

Grünenthal Group

Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward

Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...
03.03.2017 – 23:12

Acceleratio Capital N.V.

Shareholding quota of the tender offer for GfK SE reaches 19.33 percent / All completion conditions fulfilled; closing of the transaction expected in March 2017

London & Nuremberg (ots) - Acceleratio Capital N.V., a holding company controlled by funds advised by Kohlberg Kravis Roberts & Co. L.P. (together with affiliates, "KKR"), today announced the results of the voluntary public tender offer for the shares (ISIN: DE0005875306) of GfK SE ("GfK") after the expiry of the ...